Clinical trials: Orbitopathy, Graves
Healthy Volunteers
A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants
The primary objective of this trial are to assess the pharmacokinetics (PK) of a single subcutaneous (SC) administration of teprotumumab high-concentration formula (HCF) in healthy adult non-Japanese and Japanese participants and…
- Trial name
- NCT06674941
- Testing
- Teprotumumab
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Amgen
Graves Ophthalmopathy
Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease
Graves' orbitopathy (GO) affects about 50% of patients with Graves' disease (GD), and some cannot be cured by current treatments.
- Trial name
- TED (NCT03324022)
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Graves Ophthalmopathy
Rapamycin Plus Methylprednisolone Versus Methylprednisolone Alone in Active, Moderate-to-severe Graves' Orbitopathy.
This study is a randomized, controlled, multi-center clinical study, the purpose is to evaluate the efficacy and safety of rapamycin combined with methylprednisolone in the treatment of moderate to severe active GO.
- Trial name
- NCT05532072
- Testing
- Rapamycin, Methylprednisolone
- Where
- China
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Pulmonary Fibrosis, Thyroid Eye Disease
A Study to Evaluate the Safety, Preliminary Efficacy, and Pharmacokinetic Properties of LASN01 in Healthy Subjects and in Patients With Pulmonary Fibrosis or Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor that is being developed to address the fibro-inflammatory pathology of pulmonary fibrosis and TED.
- Trial name
- NCT05331300
- Testing
- LASN01
- Where
- 4 sites in Australia, Hong Kong
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Lassen Therapeutics 1 PTY LTD
TED
A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.
Multicentre, Randomized, Double-blinded, Phase I/II Clinical Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease
- Trial name
- NCT06769984
- Testing
- SCTT11
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Graves' Disease, Graves' Ophthalmopathy
Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy
Orbital Venous flow study in patients with Grave's Orbitopathy in different manifestation forms and stages, made with Color Doppler Imaging
- Trial name
- NCT00697528
- Where
- Brazil
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Thyroid Eye Disease, Graves Ophthalmopathy
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
This protocol studies the clinical outcome of patients with active thyroid disease with visually significant signs and symptoms of proptosis, pain, diplopiam lid/orbital edema, or lid/orbital erythema recommended for treatment…
- Conditions
- Thyroid Eye Disease, Graves Ophthalmopathy, Graves Disease
- Trial name
- Teprotumumab (NCT06275373)
- Testing
- Teprotumumab Injection [Tepezza]
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Graves' Ophthalmopathy
Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People
Find if the retinal function is affected in both the nonsevere and the severe stage of Graves' ophthalmopathy (GO) by comparing the retinal oxygen saturation of GO patients with that of normal people.
- Trial name
- NCT02290704
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University